A pivotal publication detailing the use of tofacitinib in patients hospitalized with COVID-19 pneumonia was released on 2021-01-01. The findings were published in the New England Journal of Medicine, as indicated by the source headline.
Background
Tofacitinib (Xeljanz, Xeljanz XR) is a medication that was investigated for its potential role in treating patients hospitalized with COVID-19 pneumonia. COVID-19 pneumonia is a severe respiratory complication of SARS-CoV-2 infection, often requiring hospitalization and intensive medical care due to significant lung inflammation and damage.
What this means
The publication of these findings indicates that tofacitinib was evaluated as a potential therapeutic option for patients with COVID-19 pneumonia. While the specific outcomes and efficacy data from the study are not detailed in the provided information, the publication itself highlights the scientific community's efforts to explore existing medications for repurposing during the pandemic. This research contributes to the broader understanding of potential treatments for severe manifestations of COVID-19.
Source
The information regarding this publication was obtained from PubMed, a comprehensive database for biomedical literature. The article, titled 'Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia', was published on 2021-01-01, and is accessible via pubmed.ncbi.nlm.nih.gov.